Is OmniAb, Inc. (OABI) a Buy, Sell, or Hold?
NASDAQ : OABI
OmniAb, Inc.
$3.08 USD
$0.84 (37.5%)
- Volume
- 2.68M
- Average Volume
- 577.81K
- Market Capitalization
- $366.8M
- P/E Ratio
- -8.56
- Dividend Yield
- 0.00%
- Price Target
- $4.00
- Year High
- $3.12
- Year Low
- $1.30
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $4.80
Company Overview
NASDAQ
Matthew W. Foehr
Biotechnology
Healthcare
OABI
89
US
USD
Liquidity Metrics
0.07
4.80
4.80
1.77
0.00
Sales & Valuation
$18.67M
9.54
1.52
-15.80
-0.18
Profitability
-$0.57
-$64.78M
-115.18%
-114.03%
-16.59%
-15.25%
P/E Metrics
-8.56
-0.16
-0.16
Analyst Price Target & Rating
$4.00
$4.00
$4.00
2/5
9 Analysts
-23.00%
Financial Health Scores
6.32
4/9
$52.26M
$290.26M
$29.98M
-$43.82M
Key Metrics (TTM)
$361.38M
9.40
-14.19
4.80
-16.59%
-17.24%
-11.16%
-6.33%
58 days
Company Executives
| Name | Title |
|---|---|
| Bill Harriman | Senior Vice President of Discovery Partnership Mgt., Technology Development & Operations |
| Christel Iffland | Senior Vice President of R&D Portfolio Management and Technology Operations |
| Amechi Nwachuku | Executive VP & Chief Operating Officer |
| Charles S. Berkman | Chief Legal Officer |
| Kurt A. Gustafson | Executive Vice President of Finance & Chief Financial Officer |
| Matthew W. Foehr | President, Chief Executive Officer & Director |
| Todd Pettingill | Vice President of Business Development & Strategy |
| Cia McCaffrey | Senior Vice President of People & Talent |
| Yasmina Noubia Abdiche | Senior Vice President of Exploratory Research |
| Bob Chen | Senior Vice President of Discovery Systems |
Poll Results
No votes yet today — be the first to share your view!
About OmniAb, Inc. (NASDAQ:OABI) Stock
OmniAb, Inc. is an American biotechnology firm focused on pioneering therapeutic antibody discovery. The company provides a sophisticated platform that allows its industry partners to access a broad spectrum of antibody repertoires and advanced screening techniques, thereby facilitating the development of next-generation treatments. Central to the OmniAb platform is the unique biological capability of proprietary genetically engineered animals, such as OmniRat, OmniChicken, and OmniMouse. These animals are modified to produce human-sequence antibodies, simplifying the creation of human therapeutic candidates. Additionally, OmniAb offers specialized technologies like OmniFlic (a transgenic rat) and OmniClic (a transgenic chicken), which address the requirements for bispecific antibody appli ... cations via a common light chain method, as well as OmniTaur, which leverages the distinct structural properties of cow antibodies for challenging targets. The company was founded in 2012 and is based in Emeryville, California.
OmniAb, Inc. (OABI) Q2 2026 Earnings Call Transcript
2026-08-07 09:54:25
OmniAb, Inc. (OABI) Q2 2026 Earnings Call Transcript
OmniAb Q2 Earnings Call Highlights
2026-08-07 02:05:23
OmniAb NASDAQ: OABI reported higher second-quarter revenue and a narrower net loss as milestone payments from partner programs increased, while the company raised its full-year 2026 revenue and year-end cash outlook.
OmniAb, Inc. (OABI) Reports Q2 Loss, Beats Revenue Estimates
2026-08-06 20:12:26
OmniAb, Inc. (OABI) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to a loss of $0.15 per share a year ago.
OmniAb Reports Second Quarter 2026 Financial Results and Business Highlights
2026-08-06 16:05:00
EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (NASDAQ: OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, today reported financial results for the three and six months ended June 30, 2026, provided operating and partner program progress, and updated 2026 financial guidance. “We are pleased to report a strong quarter and to increase our revenue and cash outlook for 2026 based on continued momentum in our business. Recent u.
2026-07-27 07:00:00
ZURICH, SWITZERLAND, July 27, 2026 -- VERAXA Biotech AG (NASDAQ: VRXA; "VERAXA" or the "Company"), an emerging leader in designing novel cancer therapies, today announced the advancement of bispecific ADC (bsADC) program VXA-222, following successful achievement of a key technical milestone in its alliance with OmniAb, Inc.
OmniAb to Report Second Quarter 2026 Financial Results on August 6
2026-07-16 08:00:00
EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (NASDAQ: OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, today announced the Company will report financial results for the three and six months ended June 30, 2026, after the close of the U.S. financial markets on Thursday, August 6, 2026, and will hold a conference call that same day beginning at 4:30 p.m. Eastern time. Conference Call and Webcast What: OmniAb conference.
OmniAb Names Amechi Nwachuku Chief Operating Officer
2026-07-13 09:00:00
OmniAb, Inc. (NASDAQ: OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, announces that it
OmniAb Names Amechi Nwachuku Chief Operating Officer
2026-07-13 08:00:00
EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ:OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, announces that it has appointed Amechi Nwachuku to the newly-created position of Executive Vice President and Chief Operating Officer, effective today. Mr. Nwachuku will be primarily responsible for managing the strategy, operations and commercial maximization of xPloration®, OmniAb's proprietary, innovative high-throu.
Frequently Asked Questions
-
What is the current OmniAb, Inc. (OABI) stock price?
-
OmniAb, Inc.(NASDAQ:OABI) stock price is $3.08 in the last trading session. During the trading session, OABI stock reached the peak price of $3.12 while $1.3 was the lowest point it dropped to. The percentage change in OABI stock occurred in the recent session was 37.5% while the dollar amount for the price change in OABI stock was $0.84.
-
OABI's industry and sector of operation?
-
The NASDAQ listed OABI is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of OABI?
-
Bill Harriman | Senior Vice President of Discovery Partnership Mgt., Technology Development & Operations
Christel Iffland | Senior Vice President of R&D Portfolio Management and Technology Operations
Amechi Nwachuku | Executive VP & Chief Operating Officer
Charles S. Berkman | Chief Legal Officer
Kurt A. Gustafson | Executive Vice President of Finance & Chief Financial Officer -
How many employees does OABI have?
-
Number of OABI employees currently stands at 89. OABI operates from 5980 Horton Street, EmeryVille, CA 94608, US.
-
Link for OABI official website?
-
Official Website of OABI is: https://www.omniab.com
-
How do I contact OABI?
-
OABI could be contacted at phone #510 250 7800 and can also be accessed through its website. OABI operates from 5980 Horton Street, EmeryVille, CA 94608, US.
-
How many shares of OABI are traded daily?
-
The average number of OABI shares traded daily for last 3 months was 577.81K.
-
What is the market cap of OABI currently?
-
The market value of OABI currently stands at $366.8M with its latest stock price at $3.08